Localized Prostate Cancer COE

CEASAR Study Reveals Long-Term Quality of Life Outcomes for Localized Prostate Cancer Treatments - Daniel Barocas & Bashir Al Hussein Al Awamlh

Details
Alicia Morgans hosts Daniel Barocas and Bashir Al Hussein Al Awamlh to discuss findings from the CEASAR study published in JAMA, which explores long-term quality of life outcomes for men with localized prostate cancer. Initiated by Dave Penson, this longitudinal study aims to enhance shared decision-making in treatment by providing data on the side effects of various prostate cancer treatments. Fo...

PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett

Details
At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials' findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses ongoin...

Radiation Outcomes Improve with Age in Localized Prostate Cancer - Mack Roach

Details
Alicia Morgans talks with Mack Roach about his research in radiation oncology and urology. Dr. Roach discusses his involvement in studies like RTOG 75-06, 86-10, and 85-31, focusing on hormones and radiation in prostate cancer. He shares insights from his analysis of pre-treatment testosterone data from 2,400 patients, revealing that age over 70 correlates with better prostate cancer-specific outc...

How Mental Health Disorders Impact Treatment Decisions in Localized Prostate Cancer - Yaw Nyame & Joshua Cabral

Details
Ruchika Talwar hosts Joshua Cabral and Yaw Nyame to explore the impact of mental health disorders on prostate cancer care. Their study, "Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders," used the Medicare database from 2004 to 2015. They found that 50% of US adults meet DSM-IV disorder criteria at some point, and ment...

Deciphering Prostate Cancer: How Genomic Biomarkers are Shaping Treatment Decisions - Paul Nguyen

Details
Neil Desai and Paul Nguyen discuss the integration of the Decipher genomic biomarker in prostate cancer treatment. The conversation centers on two trials, NRG-GU009 and GU010, which utilize Decipher genomic classifiers to tailor treatment intensity, particularly in hormonal therapy. Dr. Nguyen emphasizes the shift from traditional metrics like PSA and Gleason scores to more precise genomic classif...

Parsing the Evidence from the EMBARK Trial on a Promising New Drug Regimen in High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer - Matthew Cooperberg

Details
Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...

Correlation and Validation of Gene Expression Classifiers in Prostate Cancer: A Large-Scale Study - Daniel Spratt

Details
Aditya Bagrodia hosts Daniel Spratt to discuss the complexities of gene expression classifiers in prostate cancer. Dr. Spratt's team conducted a study involving over 50,000 patients to evaluate the interchangeability of three major gene classifiers: Decipher, Oncotype, and Polaris. Contrary to common belief, the study reveals that these tests are not functionally interchangeable, showing only mode...

Decipher Scores and PSMA PET Imaging: A Correlative Study in High-Risk Prostate Cancer - Amar Kishan

Details
Daniel Spratt engages with Amar Kishan about the role of transcriptomic profiling and PSMA PET imaging in prostate cancer. Dr. Kishan discusses a study involving 18 trials and 12,500 patients, which suggests that extra-prostatic disease is often the driver of distant metastasis in high-risk patients. The study also explores the correlation between Decipher scores and the risk of upstaging on PSMA...

PACE B Study Analysis: Acute and Late Toxicities in Prostate Cancer Radiotherapy - Ragu Ratnakumaran

Details
Phillip Koo interviews Ragu Ratnakumaran about the analysis of the PACE-B study. The study is a phase III international randomized control trial involving 874 patients with low to intermediate-risk prostate cancer. Dr. Ratnakumaran's analysis focuses on the association between acute and late genitourinary and gastrointestinal toxicities in two radiotherapy treatment arms: conventional or moderatel...

Exploring Regional Variation in Genomic Testing and Imaging in Prostate Cancer - Michael S. Leapman

Details
In an interview with Matthew Cooperberg, Michael Leapman discusses his research on the use of genomic tests and imaging in prostate cancer and the resulting national practice patterns. Leapman found significant regional variation in the utilization of these tests, with areas rich in urologists and prostate cancer care showing higher adoption rates. He also observed a correlation between increased...